Effects of Bardoxolone Methyl on Renal Perfusion

• Research type

  Research Study

• Full title

  Pilot Assessment of the Combined Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients with Chronic Kidney Disease and Type 2 Diabetes

• IRAS ID

  99705

• Contact name

  Chris McIntyre

• Sponsor organisation

  Reata Pharmaceutical Inc

• Eudract number

  2012-000806-20

• Clinicaltrials.gov Identifier

  NCT01551446

• Research summary

  The purpose of this study is to more thoroughly understand the effects of bardoxolone methyl, an investigational drug being developed by Reata Pharmaceuticals, on the kidneys of those individuals afflicted with CKD and type 2 diabetes. This study is a single-center, open-label study. Both the participants and the doctor will know when and how much drug each participant received. The drug will be provided in capsules for everyone who participates in the study; the drug is to be taken in the morning one hour before or two hours after eating. No one in this study will receive a placebo (drugs without active ingredients). Bardoxolone methyl is an investigational (experiemental) drug that is being tested to treat CKD.

• REC name

  Yorkshire & The Humber - Sheffield Research Ethics Committee

• REC reference

  12/YH/0241

• Date of REC Opinion

  12 Jul 2012

• REC opinion

  Further Information Favourable Opinion